Previous 10 | Next 10 |
2024-05-28 11:05:25 ET More on Consumer Staples XLP: Not In The Spotlight Amid Market Uncertainty XLP: Expensive With Underperformance Risk XLP: Rotate Into This Lagging Sector The consumer 'remains more likely to cruise' than crumble - Goldman Sachs ...
2024-05-26 08:15:00 ET Raging hot inflation has made it harder to find value in anything these days. A $20 bill doesn't go as far as it once did. But don't get discouraged; that money can go a long way if you know where to put it. Yes, even in the stock market, you can still get a lot for $...
2024-05-23 06:50:00 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips For investors looking at companies providing GLP-1 drugs, there are certainly plenty of factors to consider. This is a fast-growing market, but one also becoming increasingly competitive. Patie...
2024-05-22 12:42:27 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Judging which growth stocks are good long-term bets is trickier than you might expect. These fast-moving businesses can be hard to forecast, and changes in their broader industries could qu...
2024-05-22 07:51:38 ET More on Hims & Hers Health Hims & Hers: Soaring On Access To Compounded GLP-1 Drugs, Further Volatility Ahead 10 Solid Reasons To Buy Hims & Hers Stock Hims & Hers: Strong Operating Leverage And Profitability Inflection ...
2024-05-22 04:36:00 ET Hims & Hers (NYSE: HIMS) has been a great growth stock since coming public, but it's now starting to turn a profit. In this video, Travis Hoium highlights the company's financials and why the launch of GLP-1 medications could be a game-changer. *Stoc...
2024-05-21 15:14:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-05-21 09:21:57 ET More on Eli Lilly, Novo Nordisk Eli Lilly: Great Time To Divest Before It Potentially Crashes Eli Lilly Remains Expensive Here - Minimal Margin Of Safety The FTC Cracks Down On Novo Nordisk's Ozempic Eli Lilly inks radiopharma deal wort...
2024-05-21 08:15:00 ET Summary Hims & Hers Health's share price increased by over 25% after announcing the availability of compounded GLP-1 agonist weight loss drugs at a fraction of the price of branded drugs. The company aims to capitalize on the shortages of the branded dru...
2024-05-20 13:12:18 ET More on mid-day movers & stocks. CervoMed: H2 2024 Data For DLB Program A Major Inflection Point Scorpius gains on cGMP facility validation for microbial manufacturing Scorpius prices public offering of units to raise $6M Historical...
News, Short Squeeze, Breakout and More Instantly...
Hims & Hers Health Inc. Class A Company Name:
HIMS Stock Symbol:
NYSE Market:
Hims & Hers Health Inc. Class A Website:
Bringing experience from Novo Nordisk and Teva Pharmaceutical Industries, Schultz joins the Hims & Hers Board of Directors to help the company increase access to health and wellness solutions Hims & Hers Health, Inc. (“Hims & Hers”, NYSE: HIMS), the leading hea...
2024-07-20 09:00:00 ET With shares up a blistering 150% year to date, Hims & Hers Health (NYSE: HIMS) boasts everything an investor could dream of these days: rapid expansion, a vast addressable market, and a reasonable valuation. Let's explore why it is my top growth ...
Hims & Hers Health, Inc. ("Hims & Hers") (NYSE: HIMS), the leading health and wellness platform, today announced that it will report second quarter financial results after the market closes on Monday, August 5, 2024. The company will host a live conference call to discuss the results at 5...